Autopsy report · NCT02730962
Interventional Bioremediation of Microbiota in Metabolic Syndrome
Cause of deathFunding or business, also regulatory or ethics
“Delays in IND approval caused a lack of funding to conduct the trial.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 7 months before it stopped.
- 12 participants enrolled.
- Results were posted on the registry 2 years 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Conditions
- Pre-Diabetes
- Interventions
- Vancomycin; Placebo; Neomycin; Clindamycin; Fecal Microbiota Transplantation
- Participants
- 12
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris
“Lack of funding and sponsor decided to not pursue clinical trial” - Milk Oriented Microbiota
“Did not receive funding to start the trial.” - A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
“Did not receive funding for the trial.” - Pancreatic Enzyme Supplementation for Celiac Disease
“The trial was terminated prematurely by the sponsor for administrative reasons.” - A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
“The sponsor decided not to conduct the expansion part of trial (part 2)”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.